EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Change in albuminuria as a surrogate endpoint for cardiovascular and renal outcomes in patients with diabetes

Biff F Palmer

Diabetes, Obesity and Metabolism · 2023

DOI: 10.1111/dom.15030 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diabetes, Obesity and Metabolism, 2023. Verfasst von Biff F Palmer. Beteiligte Einrichtung: Department of Internal Medicine, Divison of Nephrology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic, Diabetic Nephropathies, Cardiovascular Diseases. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bayer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

For the purpose of predicting clinical outcomes in patients with diabetes and chronic kidney disease, change in albuminuria is a good candidate to be a surrogate marker for future cardiovascular events and progression of kidney disease. Spot urine albumin/creatinine ratio is convenient and recognized as a viable alternative to 24‐h albumin, with some limitations. Although there is sufficient evidence to validate its use in clinical trials as a surrogate endpoint for renal outcomes, this is not yet the case for cardiovascular outcomes. While change in albuminuria as a primary or secondary endpoint is trial‐specific, its use should be encouraged, nonetheless.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Renal Insufficiency, ChronicDiabetic NephropathiesCardiovascular DiseasesHumansAlbuminuriaGlomerular Filtration RateBiomarkers

Stichwörter der Autor:innen

albuminuriacardiovascular diseasechronic kidney diseasediabetes complicationsdiabetic nephropathyeffectivenesstype 2 diabetes mellitus

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Department of Internal Medicine, Divison of Nephrology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

Förderung

  • Bayer

Zitieren

APA

Palmer, B. F. (2023). Change in albuminuria as a surrogate endpoint for cardiovascular and renal outcomes in patients with diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15030

Vancouver

Palmer BF. Change in albuminuria as a surrogate endpoint for cardiovascular and renal outcomes in patients with diabetes. Diabetes, Obesity and Metabolism. 2023. doi:10.1111/dom.15030

BibTeX
@article{Palmer2023,
  author = {Palmer, Biff F},
  title = {Change in albuminuria as a surrogate endpoint for cardiovascular and renal outcomes in patients with diabetes},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2023},
  doi = {10.1111/dom.15030}
}
Kostenlos starten →